Atezolizumab + Chemoradiation for Small Cell Lung Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on systemic corticosteroids or other immunosuppressive medications, you may need to stop them 14 days before starting the study treatment.
What data supports the effectiveness of the drug Atezolizumab combined with chemotherapy for small cell lung cancer?
Is the combination of atezolizumab, chemotherapy, and radiation therapy generally safe for humans?
Research shows that the combination of atezolizumab with chemotherapy (carboplatin and etoposide) and radiation therapy has been studied for safety in patients with small cell lung cancer and other conditions. In a study, patients experienced some severe blood-related side effects, but these were managed by adjusting medication doses, and no severe non-blood-related side effects were reported. Overall, this combination has been considered safe for use in humans, with careful monitoring and dose adjustments as needed.678910
What makes the treatment with Atezolizumab and Chemoradiation unique for small cell lung cancer?
What is the purpose of this trial?
This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.
Research Team
Kristin A Higgins
Principal Investigator
NRG Oncology
Eligibility Criteria
This trial is for adults with a confirmed diagnosis of limited stage small cell lung cancer. Participants must have had one cycle of specific chemotherapy, be in good physical condition (ECOG 0-2), and have proper organ function. Pregnant women, those with certain medical conditions or previous treatments like immunotherapy, and individuals not using contraception are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Chemoradiation
Patients receive etoposide and cisplatin or carboplatin with radiation therapy. Cycles repeat every 21 days for 3 cycles.
Immunotherapy
Patients receive atezolizumab IV on day 1 or 2 of each chemotherapy cycle. Cycles repeat every 3 weeks for 17 cycles.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 3-Dimensional Conformal Radiation Therapy
- Atezolizumab
- Carboplatin
- Cisplatin
- Etoposide
- Intensity-Modulated Radiation Therapy
3-Dimensional Conformal Radiation Therapy is already approved in United States, European Union, Canada, Japan, China, Switzerland for the following indications:
- Various types of cancer, including gynecologic cancers
- Various types of cancer, including gynecologic cancers
- Various types of cancer, including gynecologic cancers
- Various types of cancer, including gynecologic cancers
- Various types of cancer, including gynecologic cancers
- Various types of cancer, including gynecologic cancers
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor
NRG Oncology
Collaborator